(Circulation. 1999;99:1464-1470.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
From INSERM U153 (M.B., C.D., K.S., B.H., P.G.) and Service de Biochimie (L.D., P.R., B.H.), Groupe Hospitalier Pitié-Salpêtrière, Paris; Service de Cardiologie (I.D., P.C.), Hôpital Lariboisière, Paris, France; Centre Hospitalier des Ardennes (H.H.), site de Sainte-Ode, Belgium; Service de Cardiologie A (D.K.), CHU Lille, France; Institute for Arteriosclerosis Research (E.S.-B., H.F.), University of Münster, and Department of Cardiology (E.S.-B.), Hospital of the University of Münster, Germany.
Correspondence to Pascale Guicheney, INSERM U153, Groupe Hospitalier Pitié-Salpêtrière, 47 boulevard de l'Hôpital, 75651 Paris Cedex 13, France. E-mail pguichen{at}myologie.infobiogen.fr
| Abstract |
|---|
|
|
|---|
Methods and ResultsNew specific primers allowed the amplification of the 3' part of HERG, the identification of 2 missense mutations, S818L and V822 M, in the putative cyclic nucleotide binding domain, and a 1-bp insertion, 3108+1G. Hypokalemia was a triggering factor for torsade de pointes in 2 of the probands of these families. Lastly, in a large family, a maternally inherited G to A transition was found in the splicing donor consensus site of HERG, 2592+1G-A, and a paternally inherited mutation, A341E, was identified in KCNQ1. The 2 more severely affected sisters bore both mutations.
ConclusionsThe discovery of mutations in the C-terminal part of HERG emphasizes that this region plays a significant role in cardiac repolarization. Clinical data suggests that these mutations may be less malignant than mutations occurring in the pore region, but they can become clinically significant in cases of hypokalemia. The first description of 2 patients with double heterozygosity associated with a dramatic malignant phenotype implies that genetic analysis of severely affected young patients should include an investigation for >1 mutation in the LQT genes.
Key Words: long-QT syndrome torsade de pointes hypokalemia LQT1 LQT2
| Introduction |
|---|
|
|
|---|
Mutations in KVLQT1, recently renamed KCNQ1,10 caused half of the LQTS5 11 12 in all the previous cases studied. Nevertheless, screening for mutations in KCNQ1 and HERG in large cohorts of probands has led to detection of a percentage lower than that suggested by linkage analyses.2 11 Moreover, only 13 missense mutations in KCNQ1 (out of 191 families) and 5 in HERG (out of 32 families) were identified.13 14 15 In these studies, only the membrane-spanning domains have been investigated. Thus, the inability to identify the underlying mutations may be owing to many reasons, eg, the presence of a mutation in an unexamined part of the gene and/or failure of the SSCP assay to detect a particular type of mutation.
Indeed, some mutations have already been identified in the cytoplasmic C-terminal parts of both KCNQ1 and HERG. In KCNQ1, 2 missense mutations, R539W and R555C, were found in Romano-Ward families, 16 17 in addition to an insertion-deletion in Jervell and Lange-Nielsen patients.18 In HERG, a splicing mutation,4 a missense mutation, V822 M, in the putative nucleotide binding site,19 and a 31-bp duplication were identified in the 3' part of the gene.20 This suggests that the C-terminal parts of these genes should also be analyzed for disease-causing mutations.
We therefore undertook the study of the genomic organization of the 3' part of HERG, paralleling the work of Itoh and coworkers, who recently published its complete structure.20 In this part of the gene, we identified 4 mutations, including 3 new ones: a missense mutation affecting a serine at position 818, a splice mutation, and a 1-bp insertion in the terminal part of the gene; this suggests that this region of the protein plays a significant role in cardiac repolarization. We also report the first description of 2 severely affected sisters both carrying a splice mutation in HERG and a missense mutation in KCNQ1.
| Materials and Methods |
|---|
|
|
|---|
|
Sequencing of PCR fragments was performed by the dideoxynucleotide chain termination method with fluorescent dideoxynucleotides on an ABIprism DNA sequencer (PE Applied-Biosystem).
Subjects
Subjects underwent detailed clinical and
cardiovascular examination, including a 12-lead ECG and
a 24-hour Holter recording. The QT intervals were measured on
ECG in lead II or V5 and corrected for heart rate
(QTc) using Bazett's formula. Subjects were
considered affected in cases of (1) syncopes or documented torsade de
pointes, (2) QTc>460 ms, and (3) QTc>440 ms associated with
bradycardia or abnormal T-wave pattern as previously
reported.16 One family originated from Belgium, (5969) one
from Spain, (7092) and the 2 others (10025,10626) were from France. All
probands were symptomatic.
The present study was performed after informed consent was obtained in accordance with the guidelines set down by the Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale du Groupe Hospitalier de la Pitié-Salpêtrière (Paris).
Haplotype Analysis
Genomic DNA was extracted from blood samples by standard
procedure. (CA)n microsatellite markers (D3S3521, D3S1298, D4S1564,
D4S407, D4S1612, D7S2461, D7S636, D7S483, D11S1318, D11S4088, D11S4146,
D11S1758) encompassing each LQT locus were provided by the
Généthon human genetic linkage map.21 PCR
amplifications were performed as previously
described.22
Single Strand Conformational Polymorphism (SSCP)
Analysis and Direct Sequencing of PCR Products
Two previously published primer pairs4 and 12 pairs
determined in the present study were used to amplify the
transmembrane segments and the C-terminal domain from genomic DNA. SSCP
analysis at 2 temperatures, 7°C and 25°C, was performed as
previously described.18 For each abnormal SSCP pattern,
the cosegregation with the disease was studied in the family.
Sequencing of the PCR products was performed as described above. An
additional primer pair (5'-TACCCTGAGTTCTCCGACCAC-3',
5'-AAAGGGGCAGCCACACAGC-3') was designed to amplify a 121-bp
fragment flanking the 2592+1G
A mutation (Family 5969), which
could not be detected by SSCP with the primers designed to amplify the
whole exon.
The sequences of the 2 KCNQ1 primers used to detect the second mutation of Family 5969 in exon 6 were 5'-GGGTTTGGGTTAGGCAGTTGG-3' and 5'-AAAGGGGCAGCCACACAGC-3'.
| Results |
|---|
|
|
|---|
HERG Missense Mutations in the Putative Cyclic
Nucleotide Binding Domain Associated with LQTS in 2
Families
In Family 10025, the proband was a 27-year-old woman who
experienced her first syncope with seizure at 25 with documented
torsade de pointes. She was treated by nadolol and a pacemaker. Her
2-year-old daughter had a QTc interval of 472 ms, but her parents had
normal QTc values and were asymptomatic.
The analysis of exon 10 PCR product by SSCP revealed an
aberrant pattern for the proband (Figure 1a
). This pattern was not observed in DNA
samples from >100 control subjects (data not shown). The sequence
analysis revealed a transition (C to T) resulting in a
replacement of the serine 818 by a leucine within the putative cyclic
nucleotide binding domain (Figure 1b
). Linkage
analysis with 5 polymorphic markers confirmed the
paternity. Thus, the proband is a de novo case of LQTS and has
transmitted the mutation to her daughter, who is
asymptomatic at 2 years.
|
In Family 10626, the proband, a 45-year-old woman, experienced several
syncopes during emotional stress at 43, occurring after a period of
diet. A test evidenced hypokalemia (2.8 meq/L). None of the children
aged 22, 18, and 9 years were symptomatic, but their QTc
values were 492, 433, and 457 ms, respectively. In exon 10 of
HERG, aberrant conformers were identified by SSCP in the
proband in her 3 children (Figure 1b
). Direct sequencing
identified a missense mutation, corresponding to a single base
transition (G to A) at position 2464 (Figure 1
). This mutation
results in substitution of the valine 822 by a methionine.
An Intragenic Insertion in the Exon 13 of HERG in a
LQTS Family
In Family 7092, the proband, a 32-year-old woman with anorexia
nervosa, experienced several syncopes, some of them triggered by a
ringing telephone. The diagnosis was made at 26 years in a context of
severe hypokalemia (2.1 meq/L to 2.7 meq/L on several occasions). After
potassium supplement and nadolol therapy, she was
asymptomatic. Nevertheless, there were 2
recurrences, one under erythromycin associated with nadolol
interruption, and the other during nocturnal arousal while on low dose
of nadolol (40 mg). Her father and her paternal grandmother were
asymptomatic [at the ages of 45 and 87 years],
although they had QTc values of 466 and 510 ms, respectively. Her
daughter was diagnosed at birth with a QTc interval of 454 ms.
Linkage analysis was performed on Family 7092 with
LQT1 to LQT4 loci microsatellite markers. Only
LQT2 marker analysis revealed the cosegregation of a
haplotype with the disease, suggesting that a mutation in
HERG caused LQTS in Family 7092 (Figure 2a
). KCNE1 (LQT5)
was excluded by direct sequencing. No abnormal conformer was detected
in all HERG PCR fragments by SSCP analysis; direct
sequencing of each PCR product was thus undertaken. An insertion of
a guanine at position 3108 was identified in exon 13 (Figure 2b
). This 1bp-insertion resulted in a frameshift leading to the
truncation of the protein at amino acid position 1117. This mutation
created a new site for the restriction enzyme Bgl I (Figure 2a
).
|
LQTS Associated With the Presence of a HERG Splicing
Mutation and a KCNQ1 Missense Mutation in the Same
Patients
In Family 5969, 3 girls (II-7, II-11, and II-12) experienced their
first syncopes at the ages of 2.5, 4, and 7, respectively. Two
of them, II-7 and II-11, had particularly long QTc values of 770 and
640 ms, respectively (Figure 3a
). Their
mother (I-6) had a syncope at 31 and a QTc value of 494 ms; her own
mother had died suddenly at age 20, and one of her nieces died suddenly
at 9. The father of the proband (I-5), although
asymptomatic, had a QTc value of 492 ms; one of his sisters
died suddenly at 46 after interruption of a beta blocking treatment
given for hypertension.
|
The family members were genotyped with 11 microsatellite
markers corresponding to LQT1 to LQT4. Haplotypes
were analyzed, taking into account that the 2 parents were
affected. The results suggested that the father could be a carrier of a
KCNQ1 mutation transmitted to 2 of his daughters (II-7 and
II-11) and the mother of a HERG mutation transmitted to 3 of
her daughters (II-7, II-11, II-12) and to her grandchild (III-1). In
the 2 unaffected siblings (II-9 and II-10), neither of the 2 at-risk
haplotypes was found (Figure 3b
). The 2 more severely affected
sisters (II-7 and II-11) were used as probands for LQT1 and
LQT2 screening.
SSCP analysis of KCNQ1 revealed aberrant bands for
exon 6 in all the LQT1-linked individuals (I-5, II-7, and
II-11, data not shown). Sequence analysis of PCR products
revealed a transversion at position 1022 (C to A) resulting in the
replacement of the alanine 341 by a glutamate within the S6
transmembrane domain (Figure 3c
). The loss of a restriction site
for Hha I induces the appearance of a uncut band of 247 bp
in all LQT1-linked individuals (Figure 3b
).
To determine the HERG mutation, direct sequencing was
undertaken. A G to A transition was found in the splicing donor
consensus site of exon 10 (2592+1G
A) (Figure 3e
). This
mutation induced no restriction modification. An abnormal conformer was
revealed by SSCP at 20°C using a new primer pair (see Methods; Figure 3d
). This mutation was absent in 100 unrelated controls.
The 2 more severely affected sisters (II-7 and II-11) turned out to be carriers of both the LQT1 and the LQT2 mutations. They were severely symptomatic and experienced stress-induced and rest-triggered syncopes. Because seizure occurring during syncopes was the initial presentation, LQTS was not diagnosed and propranolol (120 mg) was not started before age 16. However, the treatment did not prevent torsade de pointes recurrence, and a left cardiac sympathectomy was then performed. However, torsade de pointes persisted even after pacemaker implantation. Propranolol was then changed to nadolol (240 mg/d) and produced an important decrease in the number of syncopes. There was no recurrence for 2 years, until a gastrointestinal infection occurred with diarrhea and vomiting. Verapamil (120 mg/d) was then combined to nadolol (160 mg/d) and the pacing rate was increased to 85 bpm with good results. The sister (II-11) received propranolol (120 mg/d) at age 10 and remained asymptomatic until age 16 when syncopes resulting from documented torsade de pointes recurred. Propranolol was changed to nadolol (160 mg/d) combined with pacemaker implantation with a pacing rate of 80 bpm. Since then, she has been asymptomatic.
| Discussion |
|---|
|
|
|---|
We identified 2 missense mutations, the mutation V822 M, previously described by Satler and coworkers, in a large Irish family,19 and another missense mutation very close to the previous one, S818L. Interestingly, whereas the valine 822 was found in brain and olfactory cyclic nucleotide-gated channels and in most of the members of eag family, the serine 818 is conserved only among the members of the eag family. The discovery of these 2 mutated, highly conserved residues suggests that this region plays a significant role in regulating membrane excitability, which is probably not a direct result of the cyclic nucleotide action.
In a third family, a 1-bp insertion at position 3108 predicted to form a truncated subunit shorter of 103 amino acids with normal membrane spanning and putative cyclic nucleotide binding domains.
In the 3 families mentioned above, among the 10 affected individuals who were genotyped, only the 3 probands were symptomatic. Their first syncope occurred in adulthood between ages 25 and 45. For 2 of them, syncopes occurred while serum potassium levels were low. HERG encodes subunits that form the human IKr potassium current, and a hallmark feature of this current is its modulation by external potassium.25 26 In oocytes bathed by K+ concentrations ranging from 0.5 to 20 mmol/L, HERG current amplitude varied as a linear function of [K+]e.27 Unlike most other K+ currents, the magnitude of outward HERG current is paradoxically reduced on removal of extracellular K+, thus explaining the increased action potential and prolonged ventricular repolarization in hypokalemic patients. In addition, an increase in serum potassium corrects or reduces part of the abnormalities of repolarization in patients with chromosome 7-linked LQT,28 which was the case in our patients. Yang et al showed that the IKr blocking effects of quinidine and dofetilide, 2 antiarrhythmic agents, are increased by low extracellular potassium concentration.29
Thus, in individuals receiving IKr blockers, as with HERG mutation patients, hypokalemia would be expected to result in a disproportionate action potential prolongation favoring torsade de pointes. Our data are in favor of a critical role played by hypokalemia in the occurrence of ventricular arrhythmias in genetically affected subjects with HERG mutations.
In the large 4 generation Irish family with the V822 M mutation (described by Satler and coworkers), 16 members were considered clinically affected, on the basis of electrocardiographic and clinical criteria, but 26 were found to be genetically affected by linkage and SSCP analysis.19 No history of sudden death was reported in this family. Syncopal events were noted in 7 individuals. The majority of the V822 M carriers was asymptomatic (19 of 26, 73%).
In 3 families mentioned above and the Irish family, no stress-induced syncope occurred before age 10, and no history of sudden death was reported. This suggests that these mutations occurring in the C-terminal domain may be less malignant than mutations occurring in the pore region. Electrophysiological characterization of these HERG mutations would shed light on their molecular mechanisms and may allow prediction of clinical outcome, as has been attempted for the KCNQ1 C-terminal mutation, R555C.16 17
In contrast, in Family 5969, the fourth HERG mutation we
identified, 2592+1G
A, is a substitution which disrupts the
splice-donor sequence of intron 10 and appears more severe because 2
sudden deaths occurred at the ages of 9 and 20, and one of the 2 living
carriers had syncopes at 4 years with a 2-day coma. The paternally
inherited mutation, A341E, was the most frequently identified
KCNQ1 mutation. In this family, 2 of the sisters were
carriers of the LQT1 and LQT2 mutations. They
were severely symptomatic and experienced stress-induced
and rest-triggered syncopes starting in childhood. Only high doses of
nadolol (160 mg/d) combined with permanent pacing allowed control of
symptom recurrence. This is the first description of patients
carrying 2 mutations in 2 different LQT genes. This suggests that these
malignant forms are nevertheless compatible with life. Parents
of severely affected probands, and, when possible, other members of the
families, should be carefully examined on a clinical and
electrocardiographic basis to orient the genetic analysis
strategy.30 31
In the present study, we describe 4 families with a C-terminal mutation in HERG and 2 sisters presenting a HERG mutation associated with a second mutation in KCNQ1. We would like to draw several conclusions. First, the whole HERG gene has to be screened for mutation to identify all the LQT2 mutations and to evaluate in larger groups the phenotypic expression of these various mutations, either occurring in the C-terminal domain or in the transmembrane domains. Secondly, this is the first description of 2 mutations occurring in 2 different LQTS genes in the same patients, responsible for a malignant phenotype with syncopes due to ventricular arrhythmias, and finally prevented by the combination of nadolol and pacing. Thus, in order to identify such cases, it seems necessary to carefully examine both parents of probands, even if they are asymptomatic. Thirdly, hypokalemia induced by diet, anorexia nervosa, diarrhea, and, of course, diuretic treatment, can be a major trigger for the clinical expression of the disease. The importance of preventing hypokalemia, particularly in women (who may diet to lose weight), should be clearly explained to the untreated carriers, and be part of the counseling strategy. This should be in addition to issuing a contra-indicated drug list to prevent ventricular arrhythmias and syncopes. To more fully evaluate the role of mutations in the 3' part of HERG and potential interactions of these mutations with hypokalemia, larger studies in unselected populations are needed.
| Acknowledgments |
|---|
4P009D), the
Association Française contre les Myopathies (AFM, France), the
Direction de la Recherche Clinique des Hôpitaux de Paris (PHRC
P-920308), and the European Community (BMH4-CT960028). Received July 24, 1998; revision received December 8, 1998; accepted December 8, 1998.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
L. Xiao, J. Xiao, X. Luo, H. Lin, Z. Wang, and S. Nattel Feedback Remodeling of Cardiac Potassium Current Expression: A Novel Potential Mechanism for Control of Repolarization Reserve Circulation, September 2, 2008; 118(10): 983 - 992. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Schulze-Bahr Arrhythmia Predisposition: Between Rare Disease Paradigms and Common Ion Channel Gene Variants J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A67 - A78. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Anderson, B. P. Delisle, B. D. Anson, J. A. Kilby, M. L. Will, D. J. Tester, Q. Gong, Z. Zhou, M. J. Ackerman, and C. T. January Most LQT2 Mutations Reduce Kv11.1 (hERG) Current by a Class 2 (Trafficking-Deficient) Mechanism Circulation, January 24, 2006; 113(3): 365 - 373. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Crotti, A. L. Lundquist, R. Insolia, M. Pedrazzini, C. Ferrandi, G. M. De Ferrari, A. Vicentini, P. Yang, D. M. Roden, A. L. George Jr, et al. KCNH2-K897T Is a Genetic Modifier of Latent Congenital Long-QT Syndrome Circulation, August 30, 2005; 112(9): 1251 - 1258. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. van Heyningen and P. L. Yeyati Mechanisms of non-Mendelian inheritance in genetic disease Hum. Mol. Genet., October 1, 2004; 13(suppl_2): R225 - R233. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Zhang, G. M. Vincent, M. Baralle, F. E. Baralle, B. D. Anson, D. W. Benson, B. Whiting, K. W. Timothy, J. Carlquist, C. T. January, et al. An intronic mutation causes long QT syndrome J. Am. Coll. Cardiol., September 15, 2004; 44(6): 1283 - 1291. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. D. Anson, M. J. Ackerman, D. J. Tester, M. L. Will, B. P. Delisle, C. L. Anderson, and C. T. January Molecular and functional characterization of common polymorphisms in HERG (KCNH2) potassium channels Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2434 - H2441. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Anantharam, S. M. Markowitz, and G. W. Abbott Pharmacogenetic Considerations in Diseases of Cardiac Ion Channels J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 831 - 838. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Akhavan, R. Atanasiu, and A. Shrier Identification of a COOH-terminal Segment Involved in Maturation and Stability of Human Ether-a-go-go-related Gene Potassium Channels J. Biol. Chem., October 10, 2003; 278(41): 40105 - 40112. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. Mazzadi, X. Andre-Fouet, J. Duisit, V. Gebuhrer, N. Costes, P. Chevalier, C. Rodriguez, J.-J. Schott, H. Le Marec, P. Guicheney, et al. Cardiac retention of [11C]HED in genotyped long QT patients: a potential amplifier role for severity of the disease Am J Physiol Heart Circ Physiol, August 7, 2003; 285(3): H1286 - H1293. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. C. R. Roti, C. D. Myers, R. A. Ayers, D. E. Boatman, S. A. Delfosse, E. K. L. Chan, M. J. Ackerman, C. T. January, and G. A. Robertson Interaction with GM130 during HERG Ion Channel Trafficking. DISRUPTION BY TYPE 2 CONGENITAL LONG QT SYNDROME MUTATIONS J. Biol. Chem., November 27, 2002; 277(49): 47779 - 47785. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Tsuji, T. Opthof, K. Yasui, Y. Inden, H. Takemura, N. Niwa, Z. Lu, J.-K. Lee, H. Honjo, K. Kamiya, et al. Ionic Mechanisms of Acquired QT Prolongation and Torsades de Pointes in Rabbits With Chronic Complete Atrioventricular Block Circulation, October 8, 2002; 106(15): 2012 - 2018. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Schulze-Bahr, W. Haverkamp, L. Eckardt, P. Kirchhof, H. Wedekind, and G. Breithardt Genetic aspects in acquired long QT syndrome -- a piece in the puzzle Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K48 - K52. [Abstract] [PDF] |
||||
![]() |
L. A. Larsen, P. S. Andersen, J. Kanters, I. H. Svendsen, J. R. Jacobsen, J. Vuust, G. Wettrell, L. Tranebjarg, J. Bathen, and M. Christiansen Screening for Mutations and Polymorphisms in the Genes KCNH2 and KCNE2 Encoding the Cardiac HERG/MiRP1 Ion Channel: Implications for Acquired and Congenital Long Q-T Syndrome Clin. Chem., August 1, 2001; 47(8): 1390 - 1395. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Chevalier, C. Rodriguez, L. Bontemps, M. Miquel, G. Kirkorian, R. Rousson, F. Potet, J.-J. Schott, I. Baro, and P. Touboul Non-invasive testing of acquired long QT syndrome: Evidence for multiple arrhythmogenic substrates Cardiovasc Res, May 1, 2001; 50(2): 386 - 398. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Lupoglazoff, I. Denjoy, M. Berthet, N. Neyroud, L. Demay, P. Richard, B. Hainque, G. Vaksmann, D. Klug, A. Leenhardt, et al. Notched T Waves on Holter Recordings Enhance Detection of Patients With LQT2 (HERG) Mutations Circulation, February 27, 2001; 103(8): 1095 - 1101. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nattel Acquired delayed rectifier channelopathies: how heart disease and antiarrhythmic drugs mimic potentially-lethal congenital cardiac disorders Cardiovasc Res, November 1, 2000; 48(2): 188 - 190. [Full Text] [PDF] |
||||
![]() |
E. Ficker, D. Thomas, P. C. Viswanathan, A. T. Dennis, S. G. Priori, C. Napolitano, M. Memmi, B. A. Wible, E. S. Kaufman, S. Iyengar, et al. Novel characteristics of a misprocessed mutant HERG channel linked to hereditary long QT syndrome Am J Physiol Heart Circ Physiol, October 1, 2000; 279(4): H1748 - H1756. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Splawski, J. Shen, K. W. Timothy, M. H. Lehmann, S. Priori, J. L. Robinson, A. J. Moss, P. J. Schwartz, J. A. Towbin, G. M. Vincent, et al. Spectrum of Mutations in Long-QT Syndrome Genes : KVLQT1, HERG, SCN5A, KCNE1, and KCNE2 Circulation, September 5, 2000; 102(10): 1178 - 1185. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-E. Chiang and D. M. Roden The long QT syndromes: genetic basis and clinical implications J. Am. Coll. Cardiol., July 1, 2000; 36(1): 1 - 12. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kleinsasser, E. Kuenszberg, A. Loeckinger, C. Keller, C. Hoermann, K. H. Lindner, and F. Puehringer Sevoflurane, but not Propofol, Significantly Prolongs the Q-T Interval Anesth. Analg., January 1, 2000; 90(1): 25 - 25. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Cui, A. Kagan, D. Qin, J. Mathew, Y. F. Melman, and T. V. McDonald Analysis of the Cyclic Nucleotide Binding Domain of the HERG Potassium Channel and Interactions with KCNE2 J. Biol. Chem., May 11, 2001; 276(20): 17244 - 17251. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||